Changeflow GovPing Pharma & Drug Safety Patent Application for mRNA Design
Routine Notice Added Draft

Patent Application for mRNA Design

Favicon for changeflow.com ChangeBridge: Patent Apps - Biotech (C12N)
Published September 5th, 2023
Detected March 27th, 2026
Email

Summary

The USPTO has published patent application US20260088125A1 concerning methods for designing synthetic RNA molecules, specifically for mRNA design. The application details a process for obtaining coding sequences and selecting regions for synthetic RNA molecule production.

What changed

This document is a published patent application from the USPTO detailing a novel method for designing selectively translated mRNA molecules. The application, filed on September 5, 2023, outlines a process involving obtaining a coding sequence for a protein of interest, identifying a specific RNA sequence expressed in certain tissues, and then producing a synthetic RNA molecule with defined 5' and 3' regions and a loop region. The invention also includes synthetic RNA molecules produced by this method and related computer program products.

While this is a patent application and not a regulation, it signifies potential future developments in mRNA technology. Companies involved in biotechnology and pharmaceutical research, particularly those working with mRNA therapeutics or vaccines, should be aware of this filing as it may impact future intellectual property landscapes and technological advancements in the field. No immediate compliance actions are required, but monitoring patent filings in this area is advisable for R&D strategy.

Source document (simplified)

← USPTO Patent Applications

DESIGN OF SELECTIVELY TRANSLATED mRNAS

Application US20260088125A1 Kind: A1 Mar 26, 2026

Inventors

Tamir TULLER, Matan ARBEL, Yehuda LANDAU, Efi MOREE

Abstract

Methods of designing a synthetic RNA molecule comprising obtaining a coding sequence encoding a protein of interest; obtaining a sequence of an RNA expressed in a first tissue or cell type and not expressed or lowly expressed in a second tissue or cell type; selecting a region within the sequence of an RNA; and producing a sequence of a synthetic RNA molecule comprising from 5′ to 3′: a reverse complement to the selected region comprising a 5′ unhybridized region and a 3′ hybridized region, a loop region that does not hybridize; a region reverse complementary to 3′ hybridized region and the obtained coding sequence encoding a protein of interest are provided. Synthetic RNA molecules produced by a method of the invention and computer program products for perform a method of the invention are also provided.

CPC Classifications

G16B 25/10 C12N 15/67 G16B 15/10 G16B 40/20

Filing Date

2023-09-05

Application No.

19108578

View original document →

Named provisions

DESIGN OF SELECTIVELY TRANSLATED mRNAS

Classification

Agency
USPTO
Published
September 5th, 2023
Instrument
Notice
Legal weight
Non-binding
Stage
Draft
Change scope
Minor
Document ID
US20260088125A1

Who this affects

Applies to
Drug manufacturers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing 3254.1 Biotechnology
Activity scope
mRNA Design Biotechnology Research
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Research & Development
Topics
Biotechnology Intellectual Property

Get Pharma & Drug Safety alerts

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.

Get alerts for this source

We'll email you when ChangeBridge: Patent Apps - Biotech (C12N) publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.